O M A el Agnaf

Summary

Affiliation: Lancaster University
Country: UK

Publications

  1. ncbi Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease
    Brian J Tabner
    Spectroscopy Laboratory, Lancaster University, Lancaster, UK
    Free Radic Biol Med 32:1076-83. 2002
  2. ncbi Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue
    Angela M Bodles
    Centre for Peptide and Protein Engineering, School of Biology and Biochemistry, The Queen s University of Belfast, Medical Biology Centre, Belfast BT9 7BL, UK
    Neurosci Lett 359:89-93. 2004
  3. ncbi A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders
    Omar M A El-Agnaf
    Department of Biological Sciences, Lancaster University, Lancaster, UK
    FASEB J 18:1315-7. 2004
  4. ncbi Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma
    Omar M A El-Agnaf
    Department of Biological Sciences, Lancaster University, Lancaster LA1 4YQ, UK
    FASEB J 17:1945-7. 2003
  5. ncbi Soluble oligomers for the diagnosis of neurodegenerative diseases
    Omar M A El-Agnaf
    Department of Biological Sciences, Lancaster University, Lancaster, UK
    Lancet Neurol 2:461-2. 2003
  6. ncbi Aggregation and neurotoxicity of alpha-synuclein and related peptides
    O M A el-Agnaf
    Department of Biological Sciences, Lancaster University, Lancaster LA1 4YQ, UK
    Biochem Soc Trans 30:559-65. 2002
  7. ncbi A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on beta-amyloid and alpha-synuclein
    Brian J Tabner
    Magnetic Resonance Laboratory, Department of Biological Sciences, Lancaster University, Lancaster LA1 4YQ, UK
    Free Radic Res 40:731-9. 2006
  8. ncbi Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia
    Brian J Tabner
    Magnetic Resonance Laboratory, Lancaster University, Lancaster, LA1 4YQ, United Kingdom
    J Biol Chem 280:35789-92. 2005
  9. doi Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide
    Brian M Austen
    Department of Basic Medical Sciences, St George s Medical School, London SW17 ORE, United Kingdom
    Biochemistry 47:1984-92. 2008
  10. ncbi Alpha-synuclein and the pathogenesis of Parkinson's disease
    Francis L Martin
    Department of Biological Sciences, I E N S, Lancaster University, Lancaster LA1 4YQ, UK
    Protein Pept Lett 11:229-37. 2004

Collaborators

Detail Information

Publications22

  1. ncbi Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease
    Brian J Tabner
    Spectroscopy Laboratory, Lancaster University, Lancaster, UK
    Free Radic Biol Med 32:1076-83. 2002
    ....
  2. ncbi Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue
    Angela M Bodles
    Centre for Peptide and Protein Engineering, School of Biology and Biochemistry, The Queen s University of Belfast, Medical Biology Centre, Belfast BT9 7BL, UK
    Neurosci Lett 359:89-93. 2004
    ..Moreover, an equimolar mixture of the non-methylated and methylated peptides formed very few fibrils and toxicity was markedly reduced...
  3. ncbi A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders
    Omar M A El-Agnaf
    Department of Biological Sciences, Lancaster University, Lancaster, UK
    FASEB J 18:1315-7. 2004
    ..05) decreasing the percentage of cells stained positive for BAX. These short peptides could serve as lead compounds for the design of peptidomimetic drugs to treat PD and related disorders...
  4. ncbi Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma
    Omar M A El-Agnaf
    Department of Biological Sciences, Lancaster University, Lancaster LA1 4YQ, UK
    FASEB J 17:1945-7. 2003
    ..The detection of extracellular alpha-syn and/or its modified forms in body fluids, particularly in human plasma, offers new opportunities for the development of diagnostic tests for PD and related diseases...
  5. ncbi Soluble oligomers for the diagnosis of neurodegenerative diseases
    Omar M A El-Agnaf
    Department of Biological Sciences, Lancaster University, Lancaster, UK
    Lancet Neurol 2:461-2. 2003
  6. ncbi Aggregation and neurotoxicity of alpha-synuclein and related peptides
    O M A el-Agnaf
    Department of Biological Sciences, Lancaster University, Lancaster LA1 4YQ, UK
    Biochem Soc Trans 30:559-65. 2002
    ..Molecules with anti-aggregational and/or antioxidant properties may therefore be potential therapeutic agents...
  7. ncbi A spectroscopic study of some of the peptidyl radicals formed following hydroxyl radical attack on beta-amyloid and alpha-synuclein
    Brian J Tabner
    Magnetic Resonance Laboratory, Department of Biological Sciences, Lancaster University, Lancaster LA1 4YQ, UK
    Free Radic Res 40:731-9. 2006
    ..A similar mechanism could operate in PD and some other "protein conformational" disorders...
  8. ncbi Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia
    Brian J Tabner
    Magnetic Resonance Laboratory, Lancaster University, Lancaster, LA1 4YQ, United Kingdom
    J Biol Chem 280:35789-92. 2005
    ..We conclude that hydrogen peroxide formation during the early stages of protein aggregation may be a common mechanism of cell death in these (and possibly other) neurodegenerative diseases...
  9. doi Designing peptide inhibitors for oligomerization and toxicity of Alzheimer's beta-amyloid peptide
    Brian M Austen
    Department of Basic Medical Sciences, St George s Medical School, London SW17 ORE, United Kingdom
    Biochemistry 47:1984-92. 2008
    ..Our data support the idea that Abeta oligomers are responsible for the cytotoxic effects of Abeta and identify a potential peptide inhibitor for further development as a novel therapy for AD...
  10. ncbi Alpha-synuclein and the pathogenesis of Parkinson's disease
    Francis L Martin
    Department of Biological Sciences, I E N S, Lancaster University, Lancaster LA1 4YQ, UK
    Protein Pept Lett 11:229-37. 2004
    ..Such aggregation in the presence of redox metals may initiate Fenton reaction-mediated generation of reactive oxygen species (ROS). ROS thus generated may result in cytotoxic mechanisms such as the induction of DNA single-strand breaks...
  11. ncbi Both the D-(+) and L-(-) enantiomers of nicotine inhibit Abeta aggregation and cytotoxicity
    Susan A Moore
    Department of Biological Sciences, University of Lancaster, Lancaster LA1 4YQ, UK
    Biochemistry 43:819-26. 2004
    ..D-(+)-nicotine, being biologically much less active than L-(-)-nicotine, might be a useful therapeutic agent...
  12. ncbi Oligomerization and neurotoxicity of the amyloid ADan peptide implicated in familial Danish dementia
    Gillian Gibson
    Department of Basic Medical Sciences, St George s Hospital Medical School, London, UK
    J Neurochem 88:281-90. 2004
    ....
  13. ncbi Fe(II)-induced DNA damage in alpha-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay
    Francis L Martin
    Department of Biological Sciences, I E N S, Lancaster University, Lancaster, UK
    J Neurochem 87:620-30. 2003
    ..Overall, our data are suggestive of an enhanced susceptibility to the toxic effects of Fe(II) in neuroblastoma cells transfected with mutant alpha-syn associated with inherited forms of PD...
  14. ncbi A novel polymorphic triplet repeat in intron five of the alpha-synuclein gene: no evidence of expansion or allelic association with idiopathic Parkinson's disease in the Irish
    Owen A Ross
    Northern Ireland Regional Histocompatibility and Immunogenetics Laboratory, Blood Transfusion Building, Belfast City Hospital, Belfast BT9 7TS, UK
    Neuroreport 13:1621-5. 2002
    ..These results would suggest that polymorphism of the alpha-synuclein gene may not play as significant a role in the pathogenesis of idiopathic PD as previously hypothesised...
  15. ncbi Assemblies of Alzheimer's peptides A beta 25-35 and A beta 31-35: reverse-turn conformation and side-chain interactions revealed by X-ray diffraction
    Jeremy P Bond
    Department of Biology, Higgins Hall, Boston College, Chestnut Hill, MA 02467, USA
    J Struct Biol 141:156-70. 2003
    ....
  16. ncbi Copper-mediated formation of hydrogen peroxide from the amylin peptide: a novel mechanism for degeneration of islet cells in type-2 diabetes mellitus?
    Atef Masad
    Biomedical Sciences Unit, Department of Biological Sciences, Lancaster University, Lancaster, UK
    FEBS Lett 581:3489-93. 2007
    ..We conclude that the formation of H(2)O(2) from amylin could contribute to the progressive degeneration of islet cells in T2Dm...
  17. ncbi Gamma-synuclein and the progression of cancer
    Mushfika Ahmad
    Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates, Al Ain, PO Box 17666, United Arab Emirates
    FASEB J 21:3419-30. 2007
    ..This review will discuss the involvement of gamma-syn in cancer progression, metastasis and its potential as a marker...
  18. ncbi Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease
    Takahiko Tokuda
    Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto 602 0841, Japan, and Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Biochem Biophys Res Commun 349:162-6. 2006
    ..0001), even after adjusting for age. These findings identify in the quantification of alpha-syn from CSF a potential laboratory marker to aid the clinical diagnosis of PD...
  19. ncbi Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinson's disease and related disorders
    Dena A M Amer
    Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates University, P O Box 17666, Al Ain, United Arab Emirates
    Exp Brain Res 173:223-33. 2006
    ..These compounds could serve as lead compounds for the design of new drugs for the treatment of PD and related disorders in the future...
  20. ncbi Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease
    Omar M A El-Agnaf
    Department of Biochemistry, Faculty of Medicine and Health Science, United Arab Emirates University, Al Ain P O Box 17666, United Arab Emirates
    FASEB J 20:419-25. 2006
    ..597-0.948). These observations offer new opportunities for developing diagnostic tests for PD and related diseases and for testing therapeutic agents aimed at preventing or reversing the aggregation of alpha-syn...
  21. ncbi mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish
    Owen A Ross
    Northern Ireland Regional Histocompatibility and Immunogenetics Laboratory, Blood Transfusion Building, City Hospital, Belfast BT9 7TS, Northern Ireland, UK
    Exp Gerontol 38:397-405. 2003
    ..These findings lead one to postulate that the mt4216C variant, in linkage with the mtDNA TJ cluster, may influence mitochondrial dysfunction, resulting in an increased risk of PD...
  22. doi Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
    Brit Mollenhauer
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Exp Neurol 213:315-25. 2008
    ..Our results will likely aid future biomarker explorations in neurodegenerative conditions and facilitate target validation studies...